Cargando…
Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis
OBJECTIVES: Methotrexate (MTX) is currently the recommended first-line therapy for treating psoriatic arthritis (PsA), despite lacking clear evidence. No estimates of efficacy of MTX in usual care and no clear MTX responsive clinical or laboratory variables are currently available. This study descri...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425114/ https://www.ncbi.nlm.nih.gov/pubmed/32669451 http://dx.doi.org/10.1136/rmdopen-2020-001175 |